Anti-VWF D'D3 single-domain antibodies fuse to clotting factors
US11560436B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 13, 2020 |
| Grant date | Jan 24, 2023 |
| Priority date | — |
| Expiry date | Mar 26, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D′D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D′D3 domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.